For patients with ulcerative colitis (UC), administration of the probiotic E. coli Nissle (EcN) holds promise for alleviation of disease symptoms. The mechanisms are unclear, but it has been hypothesised that a capacity of the probiotic to outcompete potentially detrimental UC-associated E. coli strains plays an important role. However, this could previously not be confirmed in a mouse model of competition between EcN and two UC-associated strains, as reported by Petersen et al. 2011. In the present study, we re-evaluated the idea, hypothesising that delivery of EcN by a micro device dosing system (microcontainers), designed for delivery into the intestinal mucus, could support colonisation and confer a competition advantage compared to classical oral dosing. Six groups of mice were pre-colonised with one of two UC-associated E. coli strains followed by oral delivery of EcN, either in capsules containing microcontainers with freeze-dried EcN powder, capsules containing freeze-dried EcN powder, or as a fresh sucrose suspension. Co-colonisation between the probiotic and the disease-associated strains was observed regardless of dosing method, and no competition advantages linked to microcontainer delivery were identified within this setup. Other approaches are thus needed if the competitive capacity of EcN in the gut should be improved.

中文翻译：

---

通过粘膜粘附微容器将大肠杆菌 Nissle 递送至小鼠肠道并不能提高其对抗溃疡性结肠炎相关菌株的竞争能力

对于溃疡性结肠炎 (UC) 患者，服用益生菌大肠杆菌 Nissle (EcN) 有望缓解疾病症状。其机制尚不清楚，但据推测，益生菌战胜潜在有害的 UC 相关大肠杆菌菌株的能力发挥着重要作用。然而，据 Petersen 等人报道，这一点之前无法在 EcN 和两种 UC 相关菌株之间竞争的小鼠模型中得到证实。2011年。在本研究中，我们重新评估了这个想法，假设通过微装置剂量系统（微容器）递送EcN（设计用于递送到肠道粘液中），可以支持定植并赋予与传统口服给药相比的竞争优势。六组小鼠用两种 UC 相关大肠杆菌菌株中的一种进行预定植，然后口服 EcN，无论是在含有冻干 EcN 粉末的微容器胶囊中，还是在含有冻干 EcN 粉末的胶囊中，或者作为新鲜的 EcN。蔗糖悬浮液。无论给药方法如何，都观察到益生菌和疾病相关菌株之间的共定殖，并且在此设置中没有发现与微容器递送相关的竞争优势。因此，如果要提高 EcN 在肠道中的竞争能力，就需要其他方法。